Chr. Hansen will showcase research on its newest Swine probiotic at the Congress on Gastrointestinal Function in Chicago

Chr. Hansen will showcase research on its newest Swine probiotic at the Congress on Gastrointestinal Function in Chicago
Press Release | Apr 12. 2017 08:34 GMT

Research confirming the effective in vitro inhibition of the growth of E. coli will be showcased at the Congress on Gastrointestinal Function, where other central studies with livestock and poultry species for food production and biomedical research, as well as clinical and nutritional studies relevant to improving human health and well-being will be presented.

Chr. Hansen’s latest innovation in Swine Probiotics – PorcBoost® EB - has proven to be effective in vitro at inhibiting the growth of pathogenic E. coli and at the same time preventing the adherence of pathogenic E. coli to the epithelia of the intestinal wall. Likewise, when consumed, the highly-selected Bacillus strain contained in PorcBoost® EB leads to a demonstrable benefit in the performance of pigs. Piglets with reduced burdens of pathogenic E. coli are likely to have reduced frequency and severity of E. coli-induced scours, and will perform better.

This research will be showcased at the Congress on Gastrointestinal Function in Chicago – a place where academic and industry scientists gather to present the latest advances in understanding of gastrointestinal microbiology, physiology and nutritional sciences.


Inhibiting E. coli in piglets

E. coli infections give rise to high mortality rates and poor production performance in piglets. PorcBoost® EB contains a naturally-occurring, unique bacterial strain of Bacillus subtilis carefully selected for its E. coli inhibitory and competitive features. It is provided in feed in the form of spores, which are a dormant stage that can transform to a vegetative cell in the digestive tract of the pig. PorcBoost® EB – has proven to enhance daily weight gain and feed conversion, as well as improve fecal scoring.

The research on PorcBoost® EB will be showcased during a podium presentation at the 2017 CGIF in Chicago, USA. The congress showcases the latest in understanding of the gut microbiome as it interacts with the nutrition, ecology, and health of livestock species as well as humans and pets.

“The congress is a place where the latest in understanding of the gut microbiome is showcased. With microbial solutions at the very heart of Chr. Hansen’s business, it is only natural that we will be there to share our latest innovations, research and insights – in particular within the Swine category,” says Vilson Simon, Senior Vice President for Animal Health at Chr. Hansen.

Ramona Cernat and Bea Nielsen are the specialists in Swine health at Chr. Hansen who led the research projects for PorcBoost® EB:

“Research results have demonstrated that feed supplementation of newly weaned piglets with PorcBoost® EB had a numeric or significant effect on daily gain and feed conversion, as well as improved fecal scoring. The outcomes suggest that PorcBoost® EB’s protective effect is more likely to be pathogen-specific. We look forward to sharing more of the data and findings at the Congress in Chicago.”

Information about Chr. Hansen’s expanded range of microbial products and services for Animal Health will also be available at the Congress.


Science-based, Research-proven

At Chr. Hansen, ‘good-bacteria’ is at the heart of our business model, and we are first movers in innovation and technology when it comes to understanding the complexities of the probiotic modes of action and the gut microbiome – in humans and in animals. As such, our product innovations stem from our strong platforms in bioscience technologies and an in-depth understanding of the needs in the market. That is why we call our approach Science-based, Research-proven.

In the case of PorcBoost® EB, this included in vitro screening for antibiotic susceptibility, lack of virulence genes, tolerance to bile and acid pH, sporulation and antimicrobial activity against ETEC O149:K91:F4ac and O147:K89:F4, E.coli O101:K-:F5, Cl. perfringens Type A and Type C and S. typhimurium strains. The adhesion of Bacillus sp. spores and vegetative cells to Caco-2, mucus-secreting HT-29 MTX and porcine jejunal IPEC-J2 cells was also investigated. The pathogenic E. coli strains were further used as in vitro challenged models. The top lead candidates were selected for in vivo trials.


2017 Congress on Gastrointestinal Function

You can meet representatives from Chr. Hansen to learn more about PorcBoost EB, our research and all our probiotic solutions for Animal Health during the 3-day Congress on Gastrointestinal Function in Chicago from 10-12 April. You can also see Ramona Cernat, a Senior Research Scientist and specialist in Swine health at Chr. Hansen, hold a podium presentation on PorcBoost® EB on Wednesday, April 12 from at 9am:

  • PorkBoostEB: a new Bacillus subtilis-based probiotic that improves gut health in piglets R. Cernat, B. Nielsen; Chr. Hansen A/S, Hørsholm, Denmark

科汉森是为食品、营养、制药和农业行业开发天然解决方案的一家全球领先的生物科学公司。我们为各种食品、糖果、饮料、膳食补充剂、动物饲料和植物保护开发和生产发酵剂、酶、益生菌和天然色素。我们的产品创新基于大约 40,000 株微生物菌株——我们喜欢称之为“有益菌群”。我们的解决方案帮助食品制造商实现以更少的资源生产更多的产品,同时也减少了化学添加剂和其他合成物添加剂的使用,这使得我们的产品与当今世界息息相关。可持续性是科汉森改善食物和健康的愿景不可分割的一部分。2019 年,科汉森被 Corporate Knights 评为全球最可持续发展的公司,这要归功于我们为可持续发展付出的巨大努力以及我们与客户建立的众多合作伙伴关系。145 年来,我们一直在不断地为我们的合作伙伴以及全球终端消费者创造价值。令我们感到自豪的是,每天有超过 10 亿人在消费含有我们天然成分的产品。科汉森成立于 1874 年,并已在哥本哈根证券交易所上市。

共享